When a Medicare Part D enrollee hands a prescription to the pharmacist, there is roughly a 40% chance the claim will be rejected—not because the drug is unsafe or ineffective, but because the plan requires prior authorization. This administrative gate, designed to control costs, has become a major barrier to timely treatment. Patients often abandon therapy after a denial, while cash-pay pharmacies have stepped in to fill the gap, offering transparent pricing that bypasses insurance entirely. The result is a two-tier access system where the ability to pay out-of-pocket determines whether a patient gets their medication.

Two in Five Prescriptions Hit a Prior Authorization Wall

Medicare Part D plans require prior authorization for certain drugs, typically those with high costs, narrow therapeutic indices, or potential for misuse. According to a 2024 analysis by the Department of Health and Human Services, prior authorization rejection rates for Part D prescriptions hover around 40%, though rates vary by plan and drug class. For specialty medications—such as those for rheumatoid arthritis or multiple sclerosis—the rejection rate can exceed 60%.

The process begins when a physician prescribes a drug that is not on the plan's preferred list or requires step therapy. The pharmacy sends a claim; the plan's system flags it. The pharmacist informs the patient that the drug is not covered, and the patient must either pay cash, switch to an alternative, or wait while the physician submits a prior authorization request. That request can take hours to days to process, and even then, it may be denied.

Physicians report spending an average of 13 hours per week on prior authorization paperwork, according to a 2023 survey by the American Medical Association. For a single denied script, the physician's office may need to submit clinical notes, lab results, and a letter of medical necessity. The burden falls disproportionately on primary care providers, who manage multiple chronic conditions and often lack dedicated staff for appeals.

Patients frequently abandon therapy after an initial denial. A 2022 study in Health Affairs found that nearly one in four patients did not fill a prescription after a prior authorization was required, and among those who did, the median delay was 6 days. For conditions like hypertension or diabetes, a week without medication can lead to measurable deterioration in blood pressure or glucose control.

The appeals process offers a safety valve, but it is slow. Patients can request a redetermination from the plan, then an independent review, and eventually a hearing before an administrative law judge. Each step has strict deadlines, and the entire process can take weeks. During that time, the patient may go without treatment or resort to less effective alternatives.

Cash-Pay Pharmacies Emerge as Workaround for Denied Drugs

In response to the frustration with insurance-based access, a new model of cash-pay pharmacies has gained traction. Mark Cuban Cost Plus Drug Company, launched in 2022, offers over 1,000 generic medications at a flat 15% markup over manufacturing cost, plus a dispensing fee. A 30-day supply of metformin, for example, costs around $4, compared to $10–20 with insurance copays. The company does not accept insurance, so no prior authorization is needed.

GoodRx, a coupon platform, allows patients to compare cash prices at local pharmacies and often obtains discounts of 50–80% off retail. For a patient whose Part D plan rejects a statin, a GoodRx coupon can bring the price down to roughly $10–15 per month—less than many copays. The catch is that the patient must pay out-of-pocket, and that spending does not count toward the Part D deductible or out-of-pocket limit.

Independent pharmacies have long filled generics for $4–10 cash, but their role has expanded as prior authorization rejections rise. Pharmacists often help patients identify the cheapest cash option, sometimes overriding a denial by submitting a clinical note on the spot. However, independent pharmacies face thin margins and may not stock every drug, especially expensive brand-name products.

Cash-pay options trade insurance coverage for immediate access. Patients with chronic conditions who face frequent denials may find it more predictable to pay cash for a few key medications rather than navigate prior authorization each month. But this strategy works best for those who can afford the upfront cost and have the health literacy to compare prices. For lower-income patients, even $10 per month can be a burden, and skipping doses remains a common coping mechanism.

The cash-pay model also exposes a paradox: the same drug that costs $500 through insurance (after a denial) may be available for $50 cash. For instance, generic atorvastatin, a common cholesterol-lowering statin, can cost around $15 per month with a GoodRx coupon, while the insurance copay after a denial may be $40 or more, and the cash price at a traditional pharmacy without a coupon could exceed $100. The difference reflects rebates and administrative fees baked into the insurance price. Critics argue that this opacity undermines the purpose of insurance, which should pool risk and negotiate lower prices, not create a maze that only the savvy can handle.

Formulary Exclusions Shift Prescribing Patterns

Beyond prior authorization, Part D plans use formulary exclusions to steer patients toward preferred drugs. A plan may remove a blockbuster medication from its formulary mid-year, forcing patients to switch to a different agent—a practice known as non-medical switching. The switch often occurs because the plan has negotiated a better rebate with a competitor, not because the alternative is therapeutically superior.

Physicians report that these switches can harm patients. A 2023 study in JAMA Internal Medicine found that patients who were switched from a stable statin to a different statin due to formulary changes had a 12% higher rate of cardiovascular events over the following year, possibly because some patients stopped taking the new drug due to side effects or confusion. However, this was an observational study, so the association may reflect correlation rather than causation; patients who experience side effects might be more likely to discontinue the new statin, and the study could not fully control for all confounders. Nonetheless, the finding raises concerns about non-medical switching.

Insurers defend formulary exclusions as a cost-control measure that keeps premiums lower. They argue that within each drug class, multiple options are clinically equivalent, and that prior authorization and step therapy ensure patients try cheaper alternatives before moving to expensive ones. The net effect, they say, is lower spending for the system as a whole, which benefits all enrollees.

Critics counter that the savings are often illusory. When a patient is switched to a less effective drug and later requires hospitalization, the cost of that hospitalization may exceed the savings from the drug switch. A 2021 analysis by the Commonwealth Fund estimated that for every dollar saved on drug spending through formulary restrictions, an additional $0.50–1.00 was spent on medical services due to complications. The trade-off is rarely visible to the patient at the pharmacy counter.

Formulary design is opaque to patients until they try to fill a prescription. Most Medicare beneficiaries do not review their plan's formulary until they need a drug, and by then, the open enrollment period has passed. The result is that patients often discover a coverage gap only when they are sick and need treatment, adding stress to an already difficult situation.

Hospital Consolidation Magnifies Billing Complexity

The rise of hospital systems that own their own pharmacies adds another layer of complexity. When a hospital system acquires a physician practice, the physicians may be required to prescribe only from the system's formulary, which is often tied to the system's negotiated contracts with drug manufacturers. This limits the physician's ability to prescribe a drug that the patient's Part D plan covers but the system's pharmacy does not stock.

System-owned pharmacies may also refuse to accept cash-pay discount cards like GoodRx, because doing so would undercut the system's negotiated rates. A patient whose physician prescribes a drug that is on the system's formulary but requires prior authorization from the patient's Part D plan may face a catch-22: the system's pharmacy will not fill it without insurance approval, and the insurance requires prior authorization that may take days.

Bundled contracts between hospital systems and insurers can further restrict access. A system may negotiate a single contract that covers all drugs dispensed at its facilities, but that contract may not include every drug on a patient's Part D plan. When a patient needs a drug that is out-of-network for the system's pharmacy, they may be forced to go to an independent pharmacy, but the physician's prescription may be tied to the system's electronic health record, making it difficult to send elsewhere.

Vertical integration also ties drug dispensing to system revenue. Some hospital systems have purchased specialty pharmacies and require patients to fill certain medications through them. If the patient's Part D plan rejects the claim, the system's pharmacy may offer a cash price that is higher than what the patient would pay at a cash-pay competitor, but the patient may not know they have a choice. This practice has drawn scrutiny from the Federal Trade Commission, but no broad rule change has been enacted.

Patients who try to fill a denied prescription at an out-of-network pharmacy may face surprise bills. For example, a patient whose Part D plan requires prior authorization for an insulin analog may go to a cash-pay pharmacy to avoid the delay, only to find that the cash price is $300 per vial—far more than the copay would have been. The lack of price transparency across settings makes it difficult for patients to make informed choices.

Chronic Condition Patients Most Exposed to Gaps

Patients with chronic conditions—diabetes, hypertension, mental health disorders—are disproportionately affected by prior authorization and formulary restrictions. These patients often take multiple medications, and each one may have a different coverage rule. A patient with type 2 diabetes, for example, may need a statin, an ACE inhibitor, metformin, and an SGLT2 inhibitor. The statin may be covered, the ACE inhibitor may require step therapy, metformin is usually generic and covered, and the SGLT2 inhibitor may require prior authorization.

Insulin, a life-sustaining drug for many patients with diabetes, is subject to particularly aggressive utilization management. Some Part D plans require prior authorization for insulin after the first fill, meaning that a patient who has been stable on a particular insulin for years may suddenly be denied a refill. The patient must then either switch to a different insulin or go through the appeals process, risking hypoglycemia or hyperglycemia in the meantime.

Mental health medications, including SSRIs and antipsychotics, are frequently subject to step therapy. A patient prescribed sertraline may be required to try fluoxetine first, even if the patient has a history of adverse effects with fluoxetine. The step therapy requirement can delay effective treatment by weeks, during which the patient may experience worsening symptoms or require emergency care.

Cash-pay insulin programs exist but vary by manufacturer. Eli Lilly, Novo Nordisk, and Sanofi each offer patient assistance programs that cap out-of-pocket costs for uninsured or underinsured patients. However, these programs often require enrollment, proof of income, and a prescription from a physician. The administrative burden mirrors that of prior authorization, creating a parallel system that still excludes those who cannot navigate it.

Uncontrolled chronic disease drives downstream costs that are often invisible to the plan's pharmacy benefit manager. A patient who skips insulin doses due to a prior authorization delay may end up in the emergency room with diabetic ketoacidosis, costing the plan thousands of dollars—far more than the insulin would have cost. Yet the pharmacy benefit manager's budget is separate from the medical budget, so the incentive to avoid denials is weak.

Policy Fixes Target Prior Authorization Overhaul

Several policy initiatives aim to reduce the burden of prior authorization. In 2024, the Centers for Medicare and Medicaid Services (CMS) proposed a rule requiring Medicare Advantage plans to implement electronic prior authorization and respond within 72 hours for standard requests and 24 hours for urgent ones. The rule also mandates that plans provide a specific reason for denial and allow for real-time resolution at the point of care.

State-level reforms have also gained traction. As of 2025, over 20 states have passed laws requiring insurers to report prior authorization denial rates and turnaround times. Some states have adopted "gold carding" programs, which exempt physicians with high approval rates from prior authorization requirements for certain drugs. Early data from Texas, which implemented gold carding in 2022, shows a 30% reduction in prior authorization requests among participating physicians.

A bipartisan bill in Congress, the Improving Seniors' Timely Access to Care Act, would standardize prior authorization processes across Medicare Advantage and Part D plans. The bill requires plans to implement electronic submission, provide real-time denial notifications, and establish a national standard for turnaround times. It passed the House in 2023 but stalled in the Senate amid opposition from insurers who argue that it would increase administrative costs and reduce their ability to manage utilization.

Critics of the reforms note that faster prior authorization does not address the underlying issue of formulary exclusions and high drug prices. Even if a plan responds within 24 hours, the drug may still be denied because it is not on the formulary. The patient would then need to go through the appeals process or pay cash. Some advocates argue that the focus should be on limiting the number of drugs subject to prior authorization, rather than just speeding up the process.

The debate reflects a fundamental tension between cost control and access. Insurers argue that without prior authorization, drug spending would spiral, leading to higher premiums for all beneficiaries. Patient advocates counter that the current system creates barriers that harm health and increase total system costs. The policy fix, if it comes, will likely be a compromise that preserves some utilization management while reducing the friction for patients and providers.

Patients Navigate a Two-Tier Access System

In practice, the ability to obtain a denied prescription depends largely on a patient's resources and knowledge. Wealthier patients can use discount cards or buy directly from cash-pay pharmacies, absorbing the out-of-pocket cost. They may also have the time to research alternatives, call their plan, and appeal a denial. For these patients, prior authorization is an inconvenience but not a barrier.

Lower-income patients, particularly those who are dually eligible for Medicare and Medicaid, face a different reality. They may not have a credit card to pay cash, or they may not know about GoodRx. They are more likely to skip doses or switch to a less effective generic, even if the generic has a higher side-effect profile. A 2023 survey by the Kaiser Family Foundation found that 18% of Medicare beneficiaries reported not filling a prescription in the past year due to cost, and the rate was higher among those with incomes below 150% of the federal poverty level.

Pharmacists play a crucial role in bridging the gap. When a prior authorization is denied, a pharmacist can sometimes override it by submitting a clinical note—for example, documenting that the patient has tried and failed a preferred drug. This is most effective when the pharmacist has a relationship with the patient and knows their history. Independent pharmacists are more likely to perform this service, but they are a shrinking segment of the market.

Nonprofit patient assistance programs, such as those run by the Patient Advocate Foundation, help patients navigate denials and apply for manufacturer copay assistance. However, these programs are often underfunded and have eligibility criteria that exclude many patients. The application process itself can be daunting, requiring documentation of income, insurance, and medical history.

As the healthcare system evolves, a key question remains: Will policymakers prioritize streamlining prior authorization to reduce administrative burdens and improve access, or will the two-tier system persist, leaving the most vulnerable patients to bear the greatest burden? The answer will shape the future of prescription drug access for millions of Medicare beneficiaries.

This article is for informational purposes only and does not constitute medical or insurance advice. Patients should consult their healthcare provider and plan directly for guidance on their specific coverage.